/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

Silo Pharma Inc Share Price Today: Live Updates & Key Insights

Silo Pharma Inc share price today is $0.347, up -5.79%. The stock opened at $0.3688 against the previous close of $0.3643, with an intraday high of $0.37 and low of $0.347.

Silo Pharma Inc Share Price Chart

style
pb-0

Silo Pharma Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

Silo Pharma Inc Share Price Performance

$0.347 -0.0579(-5.79%) SILO at 13 Mar 2026 03:13 PM Biotechnology
Lowest Today 0.347
Highest Today 0.37
Today’s Open 0.3688
Prev. Close 0.3643
52 Week High 1.45
52 Week Low 0.22
Day’s Range: Low 0.347 High 0.37
52-Week Range: Low 0.22 High 1.45
1 day return -
1 Week return +6.6
1 month return +15.05
3 month return -14.63
6 month return -56.46
1 year return -73.68
3 year return -82.75
5 year return -
10 year return -

Silo Pharma Inc Institutional Holdings

Financial Advocates Investment Management 2.18

UBS Group AG 1.14

Vanguard Institutional Extnd Mkt Idx Tr 0.57

Vanguard Group Inc 0.57

Geode Capital Management, LLC 0.56

Fidelity Extended Market Index 0.53

TWO SIGMA SECURITIES, LLC 0.44

State Street Corporation 0.43

Tower Research Capital LLC 0.24

Northern Trust Extended Eq Market Idx 0.12

NT Ext Equity Mkt Idx Fd - L 0.12

Fidelity Series Total Market Index 0.04

Westside Investment Management, Inc. 0.00

FWL INVESTMENT MANAGEMENT, LLC 0.00

Spartan Extended Market Index Pool E 0.00

Wells Fargo & Co 0.00

JPMorgan Chase & Co 0.00

Silo Pharma Inc Market Status

Strong Buy: 0

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Silo Pharma Inc Fundamentals

Market Cap 5.16 M

PB Ratio 0.9809

PE Ratio 0.0

Enterprise Value -1.03 M

Total Assets 7.41 M

Volume 151006

Silo Pharma Inc Company Financials

Annual Revenue FY23:72102 0.1M, FY22:72102 0.1M, FY21:71264 0.1M, FY20:40923 0.0M, FY19:40569 0.0M

Annual Profit FY23:66264 0.1M, FY22:66264 0.1M, FY21:66260 0.1M, FY20:-135203 -0.1M, FY19:13182 0.0M

Annual Net worth FY23:-4242338 -4.2M, FY22:-3908551 -3.9M, FY21:3903741 3.9M, FY20:-3129865 -3.1M, FY19:-1048086 -1.0M

Quarterly Revenue Q3/2025:18025 0.0M, Q2/2025:18025 0.0M, Q1/2025:18026 0.0M, Q3/2024:18025 0.0M, Q2/2024:18025 0.0M

Quarterly Profit Q3/2025:-2662 -0.0M, Q2/2025:16566 0.0M, Q1/2025:16566 0.0M, Q3/2024:16566 0.0M, Q2/2024:16566 0.0M

Quarterly Net worth Q3/2025:-1110438 -1.1M, Q2/2025:-1204293 -1.2M, Q1/2025:-1031437 -1.0M, Q3/2024:-928814 -0.9M, Q2/2024:-931779 -0.9M

About Silo Pharma Inc & investment objective

Company Information Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University, Medspray Pharma BV, and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.

Organisation Biotechnology

Employees 3

Industry Biotechnology

CEO Mr. Eric Weisblum

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow